US Mid-Caps Step Up Capital Deployment From Billion-Dollar M&A to Buybacks

A diverse cohort of US-listed companies is accelerating strategic overhauls and capital deployment, with recent moves spanning a USD 1.28 billion cash acquisition in the software sector to a USD 13.65 billion share buyback authorization, according to recent corporate filings and people familiar with the matters.

Western Union (WU.US)

The cross-border payments company has initiated a strategic review after receiving a private equity buyout offer below USD 10 per share, prompting a recent surge in its stock. For the second quarter of 2026, Western Union reported a 37% drop in net income to USD 76.7 million, alongside a 1% revenue decline to USD 1.01 billion, which management attributed to pressures from US immigration policy changes. The company is targeting a 20% reduction in discretionary operating expenses while maintaining a quarterly dividend of USD 0.235 per share.

SunPower (SPWR.US)

The residential solar installer, which re-listed on the Nasdaq in 2025 following a corporate restructuring, is expanding its footprint in California through a USD 12 million all-stock acquisition of Cobalt Power Systems. The deal is expected to add USD 30 million in annual revenue. The company also appointed a new chief financial officer in July 2026.

Bending Spoons (BSP.US)

The Italian technology firm announced a definitive agreement to acquire software maker Airtable in an all-cash transaction valuing the target at an enterprise value of USD 1.285 billion. This marks the company's first major acquisition since its Nasdaq listing in July 2026. To support its ongoing expansion, Bending Spoons secured EUR 500 million in medium- to long-term financing.

Victoria's Secret (VSXY.US)

Benefiting from an ongoing retail turnaround strategy, the apparel retailer raised its full-year forecast after reporting a 15% year-over-year increase in first-quarter 2026 net sales to USD 1.56 billion. The company officially changed its ticker to VSXY in June 2026 to signal the next phase of its corporate transition.

SMJ International Holdings (SMJF.US)

The Singapore-based premium flooring distributor recently filed its annual 20-F report for the fiscal year ended March 31, 2026. The company continues to focus on expanding its proprietary product lines across Asian markets, though recent trading activity has remained relatively muted without major near-term catalysts.

Viking Therapeutics (VKTX.US)

Shares of the clinical-stage biopharmaceutical firm experienced a double-digit decline in July amid investor concerns over its financial runway, despite no material negative clinical updates. Viking consumed approximately USD 96 million in cash during the second quarter of 2026, ending the period with USD 502 million in liquidity. The company is targeting the release of phase 3 maintenance data for its obesity drug VK2735 later this quarter.

Aevex Corporation (AVEX.US)

The aerospace and defense solutions provider continues to operate within its core markets, focusing on specialized defense contracts and operational continuity without material near-term financial updates.

NICE (NICE.US)

The Israeli customer service software provider reported an 8% year-over-year increase in second-quarter 2026 revenue to USD 782 million, topping analyst estimates. However, the stock recently faced downward pressure as aggressive pricing strategies aimed at accelerating the transition to its new AI platform weighed on gross margins. The company reiterated its long-term target of reaching USD 3.5 billion in revenue by 2028.

Willis Towers Watson (WTW.US)

The global advisory and brokerage firm expanded its share repurchase authorization to a total of USD 13.65 billion while advancing its Propel AI efficiency program. For the second quarter of 2026, the company posted sales of USD 2.46 billion and completed the strategic acquisition of San Francisco-based broker Newfront.

CorMedix (CRMD.US)

Following a federal appeals court victory in June 2026 protecting the patents for its Minocin product, the biopharmaceutical company is scheduled to report its second-quarter financial results in mid-August. The legal win removes a key overhang for the company, which previously topped revenue estimates for the first quarter of the year.

Across these specialized sectors, companies are aggressively optimizing their balance sheets—either through significant cost-cutting measures or debt-financed acquisitions—as they navigate a transitional macroeconomic environment and shifting competitive landscapes.

This article does not constitute investment advice.